Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Genoma GeneSafe

Eurofins Genoma has introduced GeneSafe, a non-invasive prenatal test that screens for both de novo and inherited single-gene disorders. Current commercial NIPTs only screen for aneuploidies and microdeletions, the firm said. GeneSafe identifies fetal conditions that could be missed by traditional prenatal testing, detecting more than 40 severe genetic disorders that may occur in the absence of a family history of the condition. The company said it also detects disorders with an increased prevalence associated with advanced paternal age. The test requires a small blood sample and has a turnaround time of 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder, the company noted.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.